Brought to you by 
NPS Pharmaceuticals acquires Allelix
06 Aug 2003
Executive Summary
NPS Pharmacueuticals has acquired Canadian drug development company Allelix Biopharmaceuticals for approximately $47mm ($Cdn69.2mm) in stock (based on the market value of NPS' shares). Each outstanding Allelix share became 0.3238 shares of NPS common, resulting in NPS issuing approximately 7.5mm of its shares to Allelix stockholders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NPS Pharmaceuticals acquires Allelix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice